术毕单次注射帕瑞昔布钠对布托啡诺早期镇痛效果的影响

目的观察术毕单次注射帕瑞昔布钠是否增强布托啡诺的早期镇痛效果。方法拟行择期腹部手术的患者60例,随机均分为帕瑞昔布钠组(P组)和对照组(B组),均在术毕前30min静注布托啡诺0.015mg/kg、昂丹司琼8mg,术后行PCIA(布托啡诺0.15mg/kg、昂丹司琼16mg稀释至100ml);P组术毕前30min同时静注帕瑞昔布钠40mg。记录术后4、24、48h的疼痛VAS评分、Ramsay镇静评分、追加镇痛药例数、镇痛泵按压次数和不良反应发生情况。结果 P组术后4h的VAS评分、追加镇痛药人数及术后4、24h镇痛泵按压次数明显少于B组(P<0.05)。术后4h,P组有2例需追加镇痛药,显著少于B组(12例)(P<0.01)。两组术后恶心呕吐、头晕等不良反应差异无统计学意义。结论术毕前加用帕瑞昔布钠可增强单用布托啡诺镇痛时的术后早期镇痛效果,未增加不良反应发生率。     

羟考酮联合帕瑞昔布钠对腹腔镜胆囊切除术后减轻疼痛的作用

探讨羟考酮联合帕瑞昔布钠应用于腹腔镜胆囊切除术中的安全性。按照随机数字表法将102例拟行腹腔镜胆囊切除术患者分为对照组与观察组,每组各51例。其中对照组采用吗啡联合帕瑞昔布钠麻醉;观察组采用羟考酮联合帕瑞昔布钠麻醉。评价两组患者术后3、12、24、48 h疼痛情况,记录两组术后48 h内PCA按压次数及追加镇痛药物情况,统计麻醉期间不良反应情况。术后3、12、24、48 h,两组患者静息、咳嗽时疼痛评分差异有统计学意义(P0.05);观察组术后48 h内PCA有效按压次数、镇痛药物追加率明显少于对照组(P0.05)。观察组不良反应发生率11.8%,明显低于对照组的37.3%(P0.05)。腹腔镜胆囊切除期间采用羟考酮联合帕瑞昔布钠麻醉不仅可起到较好的麻醉镇痛效果,同时还可减少不良反应的发生,从而保障患者手术安全。     

帕瑞昔布钠联合盐酸羟考酮缓释片在全膝关节置换术后镇痛中的应用

目的 评估帕瑞昔布钠联合盐酸羟考酮控释片对全膝关节置换（TKA）术后镇痛的临床效果.方法选择单侧TKA术患者60例,分为帕瑞昔布钠组（A组,30例） 及帕瑞昔布钠联合盐酸羟考酮控释片组（B组,30例）.两组术毕即采用静脉注射帕瑞昔布钠40 mg q12 h镇痛.术后24 h起,A组：当视觉模拟评分（VAS）〉5分时,静脉注射帕瑞昔布钠40 mg,随后每隔12 h再静注帕瑞昔布钠40 mg;B组：当VAS〉5分时,静脉注射帕瑞昔布钠40 mg,10 min后口服盐酸羟考酮控释片10 mg,随后每隔12h静注帕瑞昔布钠40 mg并口服盐酸羟考酮控释片10 mg.观察并记录：患者术后24、32、40、48及72 h静息及运动时VAS、Ramsay镇静评分（RSS）,术后48、72 h膝关节被动活动最大可忍受度,药物不良反应情况.结果与A组比较,B组术后32、40、48、72 h的静息及运动疼痛 VAS 评分降低（P〈0.05）,镇静评分增加（P〈0.05）,术后48 h和72 h患者可忍受最大屈曲角度增大（P〈0.05）.两组均未出现严重副反应.结论 帕瑞昔布钠与盐酸羟考酮控释片联合应用符合多模式镇痛趋势,可基本实现TKA患者术后无痛的目标,使患者顺利度过术后疼痛期.     

帕瑞昔布钠用于肺叶切除术病人超前镇痛的效果

目的 评价帕瑞昔布钠用于肺叶切除术病人超前镇痛的效果.方法 择期行开胸肺叶切除术病人60例,性别不限,年龄20～64岁,体重50～80 kg,ASA分级Ⅱ或Ⅲ级,采用随机数字表法,将患者随机分为3组(n=20):对照组(C组)不给予帕瑞昔布钠;帕瑞昔布钠超前镇痛组(A组)于术前20 min静脉注射帕瑞昔布钠40 mg;帕瑞昔布钠组(B组)于缝皮时静脉注射帕瑞昔布钠40 mg.术后行自控静脉镇痛(舒芬太尼2μg/kg和盐酸雷莫司琼0.6 mg加生理盐水至100 ml,镇痛泵负荷剂量10 ml,持续背景剂量2ml/h,PCA量0.5ml,锁定时间15 min),VAS评分＞3分时静脉注射曲马多1～2mg/kg.记录术后躁动发生情况,记录术后24h内镇痛泵按压次数、有效按压次数、舒芬太尼用量及补救用药使用情况.结果 与C组比较,A组和B组术后躁动发生率降低,术后24h内镇痛泵按压次数、有效按压次数、舒芬太尼消耗量和补救用药使用率降低(P＜0.05);与B组比较,A组术后24h内镇痛泵按压次数、有效按压次数、舒芬太尼消耗量和补救用药使用率降低(P＜0.05).结论 帕瑞昔布钠用于肺叶切除术病人具有超前镇痛作用,有助于降低麻醉恢复期并发症,产生阿片类镇痛药的节俭作用.     

帕瑞昔布钠对肺癌根治术患者术后镇痛的影响

目的 观察帕瑞昔布钠对肺癌根治术患者术后镇痛效果的影响.方法 拟行肺癌根治术患者40例,随机分为两组,每组20例,分别在麻醉诱导后(研究组)和术毕(对照组)静注帕瑞昔布钠40 mg.术毕患者均行PCIA(吗啡1 mg/ml),并于术后12、24、36 h注射帕瑞昔布钠40 mg.记录患者安静痛和咳嗽痛VAS评分及Ramsay镇静评分;记录PCA需求按压次数、有效按压次数及药物用量.采用放免法测定血浆白细胞介素(IL)-6、IL-8及TNF-α浓度.结果 术后6、12 h研究组安静痛和咳嗽痛VAS评分显著低于对照组(P＜0.05).两组Ramsay镇静评分差异无统计学意义.术后6、12h研究组镇痛药用量均显著少于对照组(P＜0.05).手术结束时至术后24 h研究组IL-6与TNF-α浓度明显低于对照组(P＜0.05).术后12、24 h研究组IL-8浓度明显低于对照组(P＜0.05).结论 术前应用帕瑞昔布钠40 mg可对肺癌根治术患者产生良好的镇痛效果.     

帕瑞昔布钠在腹腔镜下宫颈癌根治术镇痛中的应用

目的观察帕瑞昔布钠用于腹腔镜宫颈癌根治术超前镇痛效果。方法行腹腔镜宫颈癌根治术患者70例,随机分为两组：帕瑞昔布钠组术前10min给予帕瑞昔布钠40mg,对照组术前给予2ml生理盐水,每隔12小时重复给药。术后均行吗啡PCIA镇痛。采用数字评价量表（NRS）记录拔管即刻、术后2、6、12、18、24h疼痛评分,记录术后24h吗啡总消耗量及不良反应。结果帕瑞昔布钠组各时点NRS疼痛评分显著低于对照组（P〈0.05）,且24h吗啡总消耗量（10.4±7.6）mg,显著少于对照组的（17.7±8.9）mg（P〈0.05）,相应的恶心呕吐及嗜睡发生较对照组为低,24h下床活动人数明显高于对照组（P〈0.05）。结论腹腔镜宫颈癌根治术前应用帕瑞昔布钠40mg可改善单纯吗啡PCIA镇痛效果,减少吗啡用量及不良反应的发生。     

羟考酮或芬太尼联合氟比洛芬酯用于开胸术后静脉镇痛的效果

目的观察和比较开胸手术患者使用羟考酮联合氟比洛芬酯与芬太尼联合氟比洛芬酯镇痛的有效性。方法选择择期开胸手术患者80例,男53例,女24例,年龄40~65岁,ASAⅠ~Ⅲ级,随机分为两组。于手术结束前15min分别静注羟考酮0.1mg/kg(O组)或芬太尼1μg/kg(F组),术后均行PCIA,镇痛泵配方为羟考酮0.8mg/kg(O组)或芬太尼8μg/kg(F组)+氟比洛芬酯4mg/kg+昂丹司琼8mg+生理盐水至150ml。记录术后2、6、12、24、36、48h的静止和咳嗽状态VAS疼痛评分和Ramsay镇静评分;记录术后48h内PCIA有效及无效按压次数、镇痛药追加例数和不良反应情况。结果术后2~48h静息和咳嗽时O组VAS疼痛评分明显低于F组(P0.01或P0.05)。两组不同时点Ramsay镇静评分差异无统计学意义。O组PCIA有效按压次数、无效按压次数和镇痛药追加例数明显少于F组(P0.05)。O组恶心、呕吐等不良反应发生率明显低于F组(P0.05)。结论羟考酮联合氟比洛芬酯可有效地缓解开胸术后疼痛,等药剂量药物镇痛效果似强于芬太尼联合氟比洛芬酯,且不良反应更少。     

术前使用帕瑞昔布钠对神经外科手术术后镇痛及凝血功能的影响

目的观察术前使用帕瑞昔布钠对神经外科手术术后镇痛及凝血功能的影响。方法择期全麻下神经外科开颅患者90例,按照随机数表法,均分为两组:帕瑞昔布组钠(P组)和对照组(C组)。P组在手术开始前30min静脉注射帕瑞昔布钠40mg,C组在手术开始前30min静脉注射生理盐水5ml。两组术后均采用舒芬太尼静脉自控镇痛(PCIA)。PCIA配方为舒芬太尼2μg/kg+托烷司琼0.2mg/kg,加生理盐水至120ml。记录两组患者术后2、4、16、24、48h的VAS评分、Ramsay评分,术后48h内PCIA总按压次数及有效按压次数,于帕瑞昔布钠给药前和给药后2h、48h测定凝血功能,并观察术后不良反应发生情况。结果 C组术后2、4、16、24、48hVAS评分明显高于P组(P0.05),术后2hP组镇静满意率明显高于C组(P0.05)。静脉注射帕瑞昔布钠前和注射2h及48h后,两组各凝血指标差异无统计学意义;术后48h内,C组总不良反应发生率明显高于P组(P0.05)。结论静脉注射帕瑞昔布钠40mg用于神经外科术后镇痛可增强舒芬太尼PCIA的镇痛效应,减少不良反应发生率,同时不影响凝血功能。     

帕瑞昔布钠对肿瘤术后患者吗啡镇痛的影响

目的 评价帕瑞昔布钠不同方式给药对肿瘤患者术后吗啡镇痛的影响.方法 60例择期肿瘤手术患者随机分为三组,每组20例.A组切皮前15 min、术后12 h静脉注射帕瑞昔布钠40 mg;B组关腹时、术后12 h静脉注射帕瑞昔布钠40 mg;C组不用帕瑞昔布钠作为对照.三组术后均应用吗啡行患者自控镇痛(PCA).记录PACU(麻醉恢复室)停留期间、首次要求镇痛时间、术后2、4、12、24、48 h的VAS评分,48 h吗啡用量以及不良反应.结果 A组和B组术后2、4 h的VAS评分低于C组(P<0.05),A组术后12 h的VAS评分低于B、C组(P<0.05);A、B组患者在PACU要求镇痛人数较C组显著减少(P<0.05);A、B组患者首次需求镇痛时问较C组延长,而A组明显长于B组(P<0.05);与C组比较.A、B组术后48 h吗啡用量显著减少,且A组少于B组(P<0.05);三组不良反应发生率差异无统计学意义.结论 在肿瘤患者术后镇痛中,帕瑞昔布钠能够在减少吗啡用量的基础上提供更好的镇痛效果,而且切皮前给药比关腹时给药更有优势.     

地佐辛联合帕瑞昔布钠超前镇痛对直肠癌术后镇痛效果观察

为探讨地佐辛与帕瑞昔布钠联合应用能否有效提高超前镇痛的效果及减少其它阿片类镇痛药物的用量,减轻直肠癌患者术后的疼痛及不良反应,将行直肠癌根治术的患者120例随机分为3组,每组40例。第一组（P组）：手术结束前30min静脉注射帕瑞昔布钠40mg;第二组（D组）：手术结束前30min静脉注射地佐辛5mg;第三组（PD组）：手术结束前30min静脉注射帕瑞昔布钠40mg和地佐辛5mg,术后所有患者行静脉自控镇痛（PCA）治疗。观察患者术后疼痛视觉模拟评分（VAS）,PCA有效按压次数和首次肛门排气、排便时间,Ramsay镇静评分,恶心、呕吐发生率等指标。结果显示,PD组患者PCA有效按压次数显著少于P组和D组（P〈O．05）;PD组患者首次肛门排气、排便时间早于P组和D组（P〈0．05）。结果表明,直肠癌根治术采用地佐辛联合帕瑞昔布钠超前镇痛加PCA治疗效果明确,可降低枸橼酸芬太尼的用量,患者胃肠功能恢复快。     

硬膜外分娩镇痛的研究进展

硬膜外分娩镇痛对分娩的影响一直存在争议.新近资料不仅提供了硬膜外分娩镇痛对产程、剖宫产率、阴道器械助产率、及新生儿影响的进展,而且它与持续性枕后位和产妇发烧的关系也受到关注.改进硬膜外分娩镇痛技术的关键是减小对分娩不利影响并保证产妇满意镇痛的重要手段.研究表明采用低浓度局麻药复合阿片类药硬膜外镇痛,设置大容量PCEA和长锁定时间的输注模式对分娩的影响最小.     

腹部手术后镇痛药需求量的影响因素

目的：分析腹部手术后患者自控静脉镇痛用药量的影响因素。方法选取2012年4月至2013年8月全麻下行腹部手术,术后接受48 h自控静脉镇痛的患者。记录患者性别、年龄、身高、体重、体重指数、手术方式、手术部位。术后静脉镇痛期间,记录用药剂量、静止和运动疼痛评分、镇静评分、心率、血压、脉搏氧饱和度以及不良反应。采用多元线性回归分析多个变量与用药量的关系。结果共有2829例（男性1611例,女性1218例）患者纳入分析。性别、年龄、体重和手术部位显著影响术后镇痛用药量。其中,体重影响最大且与术后镇痛用药量正相关,年龄与术后镇痛用药量负相关,女性用药量少于男性。身高、体重指数和手术方式不是术后镇痛用药量的决定因素。结论腹部手术患者实施术后自控静脉镇痛时要考虑体重、年龄、性别以及手术部位的影响,为患者制定专科化和个体化的镇痛方案。     

开胸手术后伤口持续输注局麻药和PCIA的镇痛效果

目的比较开胸手术后伤口持续输注局麻药和PCIA的镇痛效果。方法择期开胸非心脏手术患者60例,ASAⅠ或Ⅱ级,随机均分为两组:伤口持续输注局麻药镇痛组(A组)和PCIA组(B组)。A组患者缝皮前在切口皮下处放置镇痛泵导管,继之通过导管快速给予0.5%罗哌卡因5ml,术毕48h内以2ml/h持续输注0.5%罗哌卡因。B组患者手术结束前30min缓慢静注舒芬太尼3μg,术毕接PCA泵以2ml/h(3μg/kg舒芬太尼配置成100ml)持续泵注。分别记录患者术后2、8、12、24、36、48h安静和活动时VAS评分、Ramsay镇静评分、术后需哌替啶镇痛例数、不良反应、住院时间及总体满意率等。结果两组患者术后不同时点安静时和活动时VAS评分差异无统计学意义。与A组比较,术后不同时点A组Ramsay镇静评分明显升高(P0.05)。术后A组无一例患者发生不良反应,明显低于B组嗜睡26例(87%)、头晕11例(37%)(P0.05)、呼吸抑制2例(6%)。A组满意率29例(97%),B组25例(83%),患者术后需哌替啶镇痛A组8例(26.7%),B组7例(23.3%),两组差异均无统计学意义。结论伤口持续输注局麻药镇痛和PCIA具有同样的镇痛效果,但伤口持续输注局麻药镇痛不良反应发生率低。     

Analgesia combinada epidural-intradural para el trabajo de parto: una revisión bibliográfica sistemática cuantitativa (metaanálisis)

ObjectiveTo perform a meta-analysis on the use of combined epidural-intrathecal analgesia during labor, including intrathecal fentanyl and/or morphine compared to usual epidural techniques.Material and methodA literature search was made looking for randomized clinical trials in MEDLINE, EMBASE and Cochrane Library. The size of the effect for quantitative variables was analyzed by weighted mean difference; for qualitative variables, by odds ratio. Variables analyzed were: labor duration, type of delivery (spontaneous, instrumental and caesarean section), motor blockade, pain, and satisfaction. The analysis used in most cases was a random effects model.ResultsA total of 21 trials, which included 3.646 patients, were selected out of the 38 initially found. The type of delivery variable with its 3 subgroups was the only one to show uniformity (p > Q 0.1; I² < 50%). There were no differences in the variables analyzed except pain, which was advantageous for the group with intrathecal fentanyl or morphine by 0.55 points out of 10.ConclusionCombined analgesia including intrathecal fentanyl-morphine does not offer significant advantages compared to the standard epidural.     

Postoperative analgesia after major abdominal surgery: Fentanyl–bupivacaine patient controlled epidural analgesia versus fentanyl patient controlled intravenous analgesia

BackgroundMajor abdominal surgeries induce neurohumoral changes responsible for postoperative pain, various organ dysfunctions and prolonged hospitalization. Inadequate pain control is harmful and costly to patients thus an appropriate pain therapy to those patients must be applicated.MethodsOne hundred patients (ASA I or II) of either sex aged from 20 to 60 years were scheduled for elective major abdominal surgery. Patients were allocated randomly into two groups (fifty patients each) to receive: patient-controlled epidural analgesia with bupivacaine 0.125% and fentanyl (PCEA group), or patient controlled intravenous analgesia with fentanyl (PCIA group). Postoperative pain was assessed over 24 h using Numerical Pain Rating scale (NPRS). The frequency of rescue analgesia, sedation score and overall patient satisfaction were recorded. Any concomitant events like nausea; vomiting, shivering, pruritus or respiratory complications were recorded postoperatively.ResultsThere was a significant less pain in PCEA group at 2, 8 and 12 h. postoperative but PCIA group had less pain at immediate postoperative time. As regard sedation scale, patients of the PCEA group were significantly less sedated than PCIA group at immediate postoperative only. Overall patient satisfaction was significantly more in PCEA group.ConclusionThis study concluded that both PCEA and PCIA were effective in pain relief after major abdominal surgery but PCEA was much better in pain relief, less sedating effect and overall patient satisfaction.     

Comparison of patient-controlled epidural analgesia with and without night-time infusion following gastrectomy

To assess the analgesic efficacy and side effects of a supplementalnight-time infusion in patient-controlled epidural analgesia(PCEA) after gastrectomy, we carried out a randomized, double-blindstudy. The number of requests were lower (P<0.005) in thePCEA plus night-time infusion group than in the PCEA alone groupduring the postoperative nights. Patients who had a PCEA plusnight-time continuous infusion, slept with fewer interruptionsthan those who had only the PCEA. VAS pain scores on coughingwere significantly lower (P<0.05) in the PCEA plus infusiongroup than in the PCEA alone group during the night followingpostoperative day 1. In conclusion, a night-time infusion inPCEA following gastrectomy decreases the incidence of postoperativepain, provides a better sleep pattern, and reduces the degreeof the pain associated with coughing during the night. Br J Anaesth 2001; 87: 633–5     

瑞芬太尼静脉自控镇痛与腰-硬联合镇痛用于分娩镇痛的比较

目的比较瑞芬太尼静脉自控镇痛(PCIA)与罗哌卡因复合芬太尼腰-硬联合自控镇痛(CSEA)在分娩镇痛中的安全性和有效性。方法选择单胎足月初产妇60例,年龄22～32岁,身高156～170cm,体重60～75kg,ASAⅠ级,依据产妇自愿原则分为两组:瑞芬太尼静脉自控镇痛组(R组)和罗哌卡因复合芬太尼腰-硬联合自控镇痛组(E组),每组30例。R组瑞芬太尼背景剂量0.02μg·kg~(-1)·min~(-1),单次剂量10～20μg,锁定时间3min;E组蛛网膜下腔注射罗哌卡因2.5～3mg,然后连接硬膜外镇痛泵(0.1%罗哌卡因75ml+芬太尼2μg/ml),设置负荷剂量10ml,背景剂量8～10ml/h,单次剂量为5ml,锁定时间15min。记录产妇镇痛前、镇痛后30min的SBP、HR、SpO2;记录镇痛前、镇痛后30min和宫口开全时VAS疼痛评分、改良Bromage评分、Ramsay镇静评分;记录第一产程和第二产程时间、胎心率、新生儿Apgar评分及脐动脉血气;分析不良反应情况、产妇满意度。结果 R组VAS疼痛评分及Ramsay镇静评分明显高于E组(P0.05);R组头晕发生率明显高于E组(P0.05);两组产程时间、Bromage评分、恶心呕吐、嗜睡、皮肤瘙痒、尿潴留等不良反应情况、产妇满意度、胎心率、脐动脉血气分析及新生儿Apgar评分差异无统计学意义。结论与罗哌卡因复合芬太尼腰-硬联合自控镇痛比较,采用瑞芬太尼静脉自控镇痛有较好的镇痛效果。尽管产妇镇静深度更高,头晕发生率较多,但是对母婴无明显不良反应,可作为椎管内分娩镇痛的补充方法。     

个体化镇痛时机对硬膜外分娩镇痛效果的影响

目的观察提前预置硬膜外导管,根据产妇需要开始镇痛的个体化镇痛模式对分娩镇痛效果的影响。方法这是一项标签开放的随机对照研究。选择单胎、足月、头位妊娠初产妇,年龄18~35岁,随机分为两组。个体化组产妇在产程开始(出现规律宫缩、宫颈接近消失)行硬膜外穿刺置管,当产妇有镇痛需求且NRS评分≥5分时给予硬膜外镇痛;对照组在宫口开大1 cm时行硬膜外镇痛。主要研究终点是分娩过程最严重疼痛NRS评分及分娩时NRS评分≥7分产妇比例。结果194例产妇完成研究,分娩过程中两组最严重疼痛程度NRS评分[个体化组9(8~10)分vs对照组9(8~10)分,P=0.201]及分娩时NRS评分≥7分产妇比例[个体化组94例(96.9%)vs对照组89例(91.8%),P=0.121]差异均无统计学意义。两组不良事件发生率差异无统计学意义。结论对于单胎、足月、头位且产科评估可试行阴道分娩的产妇,根据产妇需求实施硬膜外分娩镇痛的效果与传统的镇痛时机(宫口开放1 cm)相当。     

Comparison of patient-controlled analgesia with and without a background infusion after appendicectomy in children

BACKGROUND: There have been many studies using patient-controlled analgesia (PCA) and opioids for postoperative analgesia in children. In this study, we investigated the efficacy, usefulness and analgesic consumption of two different PCA programmes [bolus dose alone (BD) or bolus dose with background infusion (BD + BI)] to evaluate postoperative analgesia for children after emergency appendicectomy. METHODS: Forty children, aged between 6 and 15 years and ASA class I or II, undergoing emergency appendicectomy were randomly allocated into two groups. The children were given a loading dose of pethidine 0.3 mg.kg-1 and 150 micro g.kg-1 bolus intravenously in group BD (n = 20) and pethidine 0.3 mg.kg-1 loading dose, 75 micro g.kg-1 bolus and 15 micro g.kg-1.h-1 background infusion in group BD + BI (n = 20). The lockout interval was 20 min in both groups. RESULTS: There were no significant differences in pain, sedation and nausea scores during the 24-h postoperative period between the groups (P > 0.05). Pethidine consumption was significantly lower in group BD + BI than that in group BD for the first 24-h period (P < 0.05). CONCLUSIONS: We demonstrated that both these PCA programmes were effective and reliable for postoperative pain relief in children. We believe that giving information about PCA to the children and their parents is useful during the preoperative period. However, the background infusion with lower bolus dose in PCA did not increase pethidine consumption.     

Labour analgesia by single shot spinal for any parturient?—A retrospective one-year single centre audit

Background

Single shot spinal (SSS) provides effective analgesia for multiparous parturients during advanced labour. Its utility in early labour or primiparous parturients may be limited by the insufficient duration of action. Regardless, SSS may offer a reasonable labour analgesia option in certain clinical scenarios. In this retrospective study, we analyse the failure rate of SSS analgesia by assessing pain after the SSS and by determining the need for additional analgesic interventions in primiparous or early-stage multiparous parturients compared to multiparous parturients in advanced labour (cervix ≥6 cm).

Methods

Following institutional ethical board approval, the patient files of all parturients receiving SSS analgesia during a 12-month period in a single centre were analysed for any recorded notes regarding recurrent pain or subsequent analgesia interventions (a new SSS, epidural, pudendal or paracervical bloc) as a marker for insufficient analgesia.

Results

A total of 88 primiparous and 447 multiparous parturients (cervix <6 cm: N = 131; cervix ≥6 cm: N = 316) received SSS analgesia. The odds ratio for the insufficient duration of analgesia was 1.94 (1.08–3.48) in primiparous and 2.08 (1.25–3.46) in early-stage multiparous parturients compared to advanced multiparous labour (p < .01). Primiparous and early-stage multiparous parturients were also 2.20 (1.15–4.20) and 2.61 (1.50–4.55) times more likely, respectively, to receive new peripheral and/or neuraxial analgesic interventions during delivery (p < .01).

Conclusions

SSS appears to provide adequate labour analgesia for the majority of parturients in whom it is used, including nulliparous and early-stage multiparous parturients. It remains a reasonable option in certain clinical scenarios, including resource-limited settings where epidural analgesia is unavailable.